The BVAS is an independent predictor of cardiovascular events and cardiovascular disease-related mortality in patients with ANCA-associated vasculitis: A study of 504 cases in a single Chinese center

Seminars in Arthritis and Rheumatism

Volumn 47, Issue 4, 2018, Pages 524-529

  Bai, Yi Hua ^a,b,c,d   Li, Zhi Ying ^a,b,c   Chang, Dong Yuan ^a,b,c   Chen, Min ^a,b,c   Kallenberg, Cees GM ^e   Zhao, Ming Hui ^a,b,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b BEIJING HOSPITAL   (China)

^c PEKING UNIVERSITY   (China)

^d KUNMING MEDICAL UNIVERSITY   (China)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ANCA; BVAS; Cardiovascular events; Vasculitis

Indexed keywords

HIGH DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; AGE; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHINESE; CONTROLLED STUDY; DISEASE ASSESSMENT; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; COMPLICATION; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; YOUNG ADULT;

EID: 85029214506     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2017.07.004     Document Type: Article

References (38)

1. Jennette, J.C., Falk, R.J., Bacon, P.A., et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 (2013), 1–11.
2. Guillevin, L., Cordier, J.F., Lhote, F., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 40 (1997), 2187–2198.
3. Flossmann, O., Berden, A., de Groot, K., et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70 (2011), 488–494.
4. Suppiah, R., Judge, A., Batra, R., et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res 63 (2011), 588–596.
5. Li, Z.Y., Gou, S.J., Chen, M., Zhao, M.H., Predictors for outcomes in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation: a study of 89 cases in a single Chinese center. Semin Arthritis Rheum 42 (2013), 515–521.
6. Abril, A., Calamia, K.T., Cohen, M.D., The Churg Strauss syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum 33 (2003), 106–114.
7. Zhao, M.H., Lockwood, C.M., A comprehensive method to purify three major ANCA antigens: proteinase 3, myeloperoxidase and bactericidal/permeability-increasing protein from human neutrophil granule acid extract. J Immunol Methods 197 (1996), 121–130.
8. Jennette, J.C., Rapidly progressive crescentic glomerulonephritis. J Ky Med Assoc 76 (1978), 3693–3694.
9. Li, Z.Y., Chang, D.Y., Zhao, M.H., Chen, M., Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol 66 (2014), 1920–1926.
10. Hellmich, B., Flossmann, O., Gross, W.L., et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66 (2007), 605–617.
11. Luqmani, R.A., Bacon, P.A., Moots, R.J., et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87 (1994), 671–678.
12. Chen, W.W., Gao, R.L., Liu, L.S., et al. Essentials of Report on cardiovascular diseases in China 2014. Chin Circ J (in Chinese) 30 (2015), 617–622.
13. Ntatsaki, E., Watts, R.A., Scott, D.G., Epidemiology of ANCA-associated vasculitis. Rheum Dis Clin North Am 36 (2010), 447–461.
14. Lai, Q.Y., Ma, T.T., Li, Z.Y., Chang, D.Y., Zhao, M.H., Chen, M., Predictors for mortality in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a study of 398 Chinese patients. J Rheumatol 41 (2014), 1849–1855.
15. He, J., Gu, D., Wu, X., et al. Major causes of death among men and women in China. N Engl J Med 53 (2005), 1124–1134.
16. Brijker, F., Magee, C.C., Tervaert, J.W., O'Neill, S., Walshe, J.J., Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies. Clin Nephrol 52 (1999), 344–351.
17. Faurschou, M., Mellemkjaer, L., Sorensen, I.J., Svalqaard Thomsen, B., Dreyer, L., Baslund, B., Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 60 (2009), 1187–1192.
18. Morgan, M.D., Turnbull, J., Selamet, U., et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 60 (2009), 3493–3500.
19. Arbore, G., Kemper, C., A novel “complement–metabolism–inflammasome axis” as a key regulator of immune cell effector function. Eur J Immunol 46 (2016), 1563–1573.
20. Kalbitz, M., Fattahi, F., Grailer, J.J., et al. Complement-induced activation of the cardiac NLRP3 inflammasome in sepsis. FASEB J 30 (2016), 3997–4006.
21. Steyers, C.M. 3rd, Miller, F.J. Jr., Endothelial dysfunction in chronic inflammatory disease. Int J Mol Sci 15 (2014), 11324–11349.
22. Castellon, X., Boqdanova, V., Chronic inflammatory diseases and endothelial dysfunction. Aging Dis 7 (2016), 81–89.
23. Cohen Tervaert, J.W., Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol 27 (2013), 33–44.
24. Faccini, A., Kaski, J.C., Camici, P.G., Coronary microvascular dysfunction in chronic inflammatory rheumatoid disease. Eur Heart J 37 (2016), 1799–1806.
25. Booth, A.D., Jayne, D.R., Kharbanda, R.K., et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 109 (2004), 1718–1723.
26. Raza, K., Carruthers, D.M., Stevens, R., Filer, A.D., Townend, J.N., Bacon, P.A., Infliximab leads to a rapid but transient improvement in endothelial function in patients with primary systemic vasculitis. Ann Rheum Dis 65 (2006), 946–948.
27. Gonzalez-Juanatey, C., Testa, A., Garcia-Castelo, A., Garcia-Porrua, C., Llorca, J., Gonzalez-Gay, M.A., Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody. Arthritis Rheum 51 (2004), 447–450.
28. Profumo, E., Di Franco, M., Buttari, B., et al. Biomarkers of subclinical atherosclerosis in patients with autoimmune disorders. Mediators Inflamm 2012 (2012), 44–48.
29. Wållberq-Jonsson, S., Cvetkovic, J.T., Sundqvist, K.G., Lefvert, A.K., Rantapää-Dahlqvist, S., Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 29 (2002), 875–882.
30. Tani, C., Mosca, M., d'Ascanio, A., et al. Chronic inflammation and endothelial dysfunction: analysis of a cohort of patients with SLE and UCTD. Reumatismo 58 (2006), 212–218.
31. Sabio, J.M., Vargas-Hitos, J., Zamora-Pasadas, M., et al. Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 36 (2009), 2204–2211.
32. Kakuta, K., Dohi, K., Sato, Y., et al. Chronic inflammatory disease is an independent risk factor for coronary flow velocity reserve impairment unrelated to the processes of coronary artery calcium deposition. J Am Soc Echocardiogr 29 (2016), 173–180.
33. Ma, T.T., Huang, Y.M., Wang, C., Zhao, M.H., Chen, M., Coagulation and fibrinolysis index profile in patients with ANCA-associated vasculitis. PLoS One, 9, 2014, e97843.
34. Hilhorst, M., Winckers, K., Wilde, B., van Oerle, R., ten Cate, H., Tervaert, J.W., Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission arehypercoagulable. J Rheumatol 40 (2013), 2042–2046.
35. Pagnoux, C., Chironi, G., Simon, A., Guillevin, L., Atherosclerosis in ANCA-associated vasculitides. Ann N Y Acad Sci 1107 (2007), 11–21.
36. Terrier, B., Chironi, G., Pagnoux, C., et al. Factors associated with major cardiovascular events in patients with systemic necrotizing vasculitides: results of a longterm followup study. J Rheumatol 41 (2014), 723–729.
37. Montecucco, F., Favari, E., Norata, G.D., et al. Impact of systemic inflammation and autoimmune diseases on apoA-1 and HDL plasma levels and functions. Handb Exp Pharmacol 224 (2015), 455–482.
38. Robson, J., Doll, H., Suppiah, R., et al. Damage in the ANCA-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis 74 (2015), 177–184.